Computer-Aided Identification of Kinase-Targeted Small Molecules for Cancer: A Review on AKT Protein

Author:

Primavera Erika1ORCID,Palazzotti Deborah1,Barreca Maria Letizia1,Astolfi Andrea1ORCID

Affiliation:

1. Department of Pharmaceutical Sciences, “Department of Excellence 2018–2022”, University of Perugia, 06123 Perugia, Italy

Abstract

AKT (also known as PKB) is a serine/threonine kinase that plays a pivotal regulatory role in the PI3K/AKT/mTOR signaling pathway. Dysregulation of AKT activity, especially its hyperactivation, is closely associated with the development of various human cancers and resistance to chemotherapy. Over the years, a wide array of AKT inhibitors has been discovered through experimental and computational approaches. In this regard, herein we present a comprehensive overview of AKT inhibitors identified using computer-assisted drug design methodologies (including docking-based and pharmacophore-based virtual screening, machine learning, and quantitative structure–activity relationships) and successfully validated small molecules endowed with anticancer activity. Thus, this review provides valuable insights to support scientists focused on AKT inhibition for cancer treatment and suggests untapped directions for future computer-aided drug discovery efforts.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference96 articles.

1. Defining the Akt1 interactome and its role in regulating the cell cycle;Duggal;Sci. Rep.,2018

2. AKT/PKB Signaling: Navigating the Network;Manning;Cell,2017

3. Targeting PI3K/Akt signal transduction for cancer therapy;He;Signal Transduct. Target. Ther.,2021

4. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?;Martorana;Front. Pharmacol.,2021

5. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region;Bellacosa;Science,1991

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3